Design Therapeutics, Inc. launches an IPO.

IPO of Design Therapeutics, Inc. (DSGN) will take place on March 25, 2021. Design Therapeutics is a preclinical-stage biopharmaceutical company pioneering novel small-molecule therapeutic candidates that are designed to be disease-modifying and target the underlying cause of inherited diseases. The company uses its own CeneTAC platform to design and develop therapeutic candidates for the treatment of inherited diseases caused by an increase in the number of nucleotide repeats. GeneTAC is a new class of small molecules designed to target a wide range of diseases. GeneTAC molecules are heterobiofunctional, which means they are made up of two main parts, each designed to perform its unique function.

The listed bookrunners are Goldman Sachs, SVB Leerink and Piper Sandler.